DOI: https://dx.doi.org/10.18203/issn.2454-2156.IntJSciRep20223040
Published: 2022-11-23

Gut microbiota in human health: insights and discussion on the role of probiotics

Sudhanshu Patwari

Abstract


Gut microbiota remains stable and individualized throughout life, but there are inter-species or intra-species variations that may be controlled by various environmental factors. Several diseases may be associated with dysbiosis like inflammatory bowel disease (IBD), obesity, diabetes mellitus, irritable bowel syndrome (IBS), gastric and colon cancer, and sometimes colorectal polyps, non-alcoholic steatohepatitis (NASH), and liver cirrhosis, because of the gut-derived neurotoxins. There is a 10% to 30% risk of development of post-infectious IBS despite the beneficial effects of a low FODMAP diet on IBS symptoms. This diet reduces the luminal concentration of one of the most common bacteria that is the Bifidobacterium. Therefore, probiotics help in the restoration of normal gut microbiota, are a valuable tool in the treatment of certain diseases and help in recovering microbial balance in the gut. Bifidobacterium W11 is a novel probiotic with certain special characteristics that can be of benefit in dysbiosis. This review evaluates gut microbiota dysbiosis, associated complications of dysbiosis, and benefits of treatment with probiotics based on focused group discussions of various experts from India, followed by guidance statements based on analysis of published literature. The beneficial effects of Bifidobacterium longum W11 (B. longum W11) in the management of IBS, IBD, and liver diseases have been elaborated. The proposed management strategy can effectively aid the management of gut dysbiosis in several gastrointestinal conditions and help in understanding the judicious use of probiotics.


Keywords


Gut microbiota, Probiotics, IBS, IBD, Bifidobacterium longum W11

Full Text:

PDF

References


Clemente JC, Ursell LK, Parfrey LW, Knight R. The impact of the gut microbiota on human health: An integrative view. Cell 2012;148(6):1258-70.

Ortigão R, Nunes PP, Ribeiro MD, Libanio D. Gastrointestinal microbiome – What we need to know in clinical practice. GE Port J Gastroenterol 2020;27(5):336-51.

Jackson MA, Goodrich JK, Maxan ME, Freedberg DE, Abrams JA, Poole AC, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65(5):749-56.

Ramirez J, Guarner F, Fernandez LB, Maruy A, Sdepanian VL, Cohen H. Antibiotics as major disruptors of gut microbiota. Front Cell Infect Microbiol 2020;10:572912.

Janeiro MH, Ramírez MJ, Milagro FI, Martínez JA, Solas M. Implication of trimethylamine n-oxide (TMAO) in disease: Potential biomarker or new therapeutic target. Nutrients 2018;10(10):1398.

Bishehsari F, Magno E, Swanson G, Desai V, Voigt RM, Forsyth CB, et al. Alcohol and gut-derived inflammation. Alcohol Res. 2017;38(2):163-71.

Madison A, Kiecolt-Glaser JK. Stress, depression, diet, and the gut microbiota: human–bacteria interactions at the core of psychoneuroimmunology and nutrition. Curr Opin Behav Sci. 2019;28:105-10.

Girardin M, Seidman EG. Indications for the use of probiotics in gastrointestinal diseases. Dig Dis. 2011;29(6):574-87.

Kechagia M, Basoulis D, Konstantopoulou S, Dimitriadi D. Health benefits of probiotics: A review. ISRN Nutr. 2013;2013:481651.

Chong PP, Chin VK, Looi CY, Wong WF, Madhavan P, Yong VC. The microbiome and irritable bowel syndrome – A review on the pathophysiology, current research and future therapy. Front Microbiol. 2019;10:1136.

Pozuelo M, Panda S, Santiago A, Mendez S, Accarino A, Santos J, et al. Reduction of butyrate- and methane-producing microorganisms in patients with irritable bowel syndrome. Sci Rep 2015;5:12693.

Pittayanon R, Lau JT, Yuan Y, Leontiadis GI, Tse F, Surette M, et al. Gut microbiota in patients with irritable bowel syndrome-A systematic review. Gastroenterology 2019;157(1):97-108.

WGO Review Team. Probiotics and prebiotics. World Gastroenterology Organisation Global Guidelines. 2017. Available on: https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-english-2017.pdf. Assessed: 5th Sep 2022

Zhang T, Zhang C, Zhang J, Sun F, Duan L. Efficacy of probiotics for irritable bowel syndrome: A systematic review and network meta-analysis. Front Cell Infect Microbiol 2022;12:859967.

Llorente C, Schnabl B. The gut microbiota and liver disease. Cell Mol Gastroenterol Hepatol 2015;1(3):275-84.

Craven L, Rahman A, Parvathy SN, Beaton M, Silverman J, Qumosani K, et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: A randomized control trial. Am J

Gastroenterol. 2020;115(7):1055-65.

Sharma K, Pant S, Misra S, Dwivedi M, Misra A, Narang S et al. Effect of rifaximin, probiotics, and l-ornithine l-aspartate on minimal hepatic encephalopathy: A randomized controlled trial. Saudi J Gastroenterol 2014;20(4):225-232.

Cao Q, Yu CB, Yang SG, Cao HC, Chen P, Deng M, et al. Effect of probiotic treatment on cirrhotic patients with minimal hepatic encephalopathy: A meta-analysis. Hepatobiliary Pancreat Dis Int 2018;17(1):9-16.

Perumpail BJ, Li AA, John N, Sallam S, Shah ND, Kwong W et al. The therapeutic implications of the gut microbiome and probiotics in patients with NAFLD. Diseases 2019;7(1):27.

Kiely CJ, Pavli P, O'Brien CL. The role of inflammation in temporal shifts in the inflammatory bowel disease mucosal microbiome. Gut Microbes 2018;9(6):477-85.

Pierro FD. Bifidobacterium longum W11: An antibiotic-resistant probiotic. Nutrafoods 2017;16:75-7.

Fanigliulo L, Comparato G, Aragona G, Cavallaro L, Iori V, Maino M, et al. Role of gut microflora and probiotic effects in the irritable bowel syndrome. Acta Biomed 2006;77(2):85-9.

Valdovinos-Díaz MÁ, Abreu AAT, Frati-Munari AC. Clinical experience with a synbiotic (Bifidobacterium longum AW11- Fos cc. Actilight) in the relieve of constipation and other digestive symptoms. Med Int Mex 2017;33(4):476-86.

Malaguarnera M, Greco F, Barone G, Gargante MP, Malaguarnera M, Toscano MA. Bifidobacterium longum with fructo-oligosaccharide (FOS) treatment in minimal hepatic encephalopathy: A randomized, double-blind, placebo-controlled study. Dig Dis Sci. 2007;52(11):3259-65

Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R et al. Bifidobacterium longum with fructo-oligosaccharides in patients with nonalcoholic steatohepatitis. Dig Dis Sci 2012;57(2):545-53.

Pierro FD, Pane M. Bifidobacterium longum W11: Uniqueness and individual or combined clinical use in association with rifaximin. Clin Nutr ESPEN. 2021;42:15-21.

Dong J, Ping L, Cao T, Sun L, Liu D, Wang S, et al. Immunomodulatory effects of the Bifidobacterium longum BL-10 on lipopolysaccharide-induced intestinal mucosal immune injury. Front Immunol 2022;13:947755.

Perdomo CM, Frühbeck G, Escalada G. Impact of nutritional changes on nonalcoholic fatty liver disease. Nutrients 2019;11(3):677.

Yao S, Zhao Z, Wang W, Liu X. Bifidobacterium longum: Protection against inflammatory bowel disease. J Immunol Res. 2021;2021:8030297